Table 1.

Patient groups according to reasons for IVIg treatment.

	n (%)
Group 1: Patients requiring antiinflammatory treatment but complicated with secondary infection and/or sepsis	17 (36.9)
Secondary infection	12 (26.1)
Sepsis	5 (10.9)
Group 2: Patients with Covid-19 related complications	18 (39.1)
Progressive disease refractory to other antiinflammatory agents	12 (26.1)
Myocarditis/adult multisystem inflammatory syndrome	3 (6.5)
Hemophagocytic lymphohystiocytosis like syndrome	3 (6.5)
Group 3: Patients with other complications non-specific to Covid-19	11 (23.9)
Hematologic	5 (10.9)
Acute myelogenous leukemia	2 (4.3)
Hypogammaglobulinemia with chronic lymphocytic leukemia	2 (4.3)
Trombocytopenia	1 (2.2)
Neurologic	4 (8.6)
Postcovid myopathy	2 (4.3)
Postcovid Guillian-Barre syndrome	1 (2.2)
Myastenia gravis	1 (2.2)
Vasculitic	2 (4.3)
Kawasaki	1 (2.2)
Granulomatosis with polyangiitis	1 (2.2)

COVID-19: coronavirus disease 2019, n: number.